16:39:59 Europe / Stockholm

Prenumeration

2023-11-13 10:04:00

Redeye reviews the case of Alzecure in the wake of the company’s pipeline progress and Q3 report. We continue to see an interesting neurology platform case with an eventful future ahead. Throughout the quarter, there has been additional interesting progress relating to all of its platforms.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/